Glaukos Submits US IDE for Clinical Study of iStent Infinite in Refractory Glaucoma

January 5, 2018: By Jon Swedien

Glaukos submitted an investigational device exemption (IDE) application to the US FDA to study its iStent Infinite Trabecular Micro-Bypass System for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in refractory glaucoma patients, the San Clemente, California, company announced Jan. 3.

The iStent Infinite is made up of three heparin-coated titanium stents preloaded into an auto-injection system that allows the surgeon to inject stents around Schlemm’s canal across a span of five to six hours. Once in place, the stents are designed to lower IOP by restoring the natural outflow of aqueous humor, Glaukos said.

In the IDE application, Glaukos proposes to conduct a prospective, multi-center, single-arm clinical trial to evaluate safety and performance of the iStent Infinite in about 65 refractory subjects or subjects on maximally tolerated ocular hypotensive medications. The proposed primary endpoint is a 20 percent or greater reduction in IOP from baseline at 12 months on the same or fewer medications, Glaukos said. The company said it plans to use the trial results as the basis for seeking FDA clearance via a 510(k) submission.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023